The vasculature forms an intrinsic functional component of the lung and its development must be tightly regulated and coordinated with lung epithelial morphogenesis. Vascular endothelial growth factor (VEGF) and its receptors are highly expressed in a complementary pattern in the lungs during embryonic development. VEGF is expressed by epithelium and the receptors in the surrounding mesenchyme. To determine the function of VEGF in lung formation, we inhibited its activity using a soluble receptor in lung renal capsule grafts. Inhibition of VEGF results in inhibition of vascular development and significant alteration in epithelial development. Epithelial proliferation is inhibited, sacculation is impaired, and the epithelium undergoes apoptosis. Interestingly, when VEGF is attenuated, epithelial differentiation still proceeds, as shown by acquisition of both proximal and distal markers. These data show that VEGF co-ordinates epithelial and vascular development. It is required for the development of the lung vasculature and the vasculature is necessary for epithelial proliferation and morphogenesis, but not for cell differentiation. q
Introduction
Development of the lungs begins with endodermal budding from the ventral foregut at embryonic day 9.5 (E9.5) in the mouse. Growth and branching of the endoderm give rise to the airways (Boyden, 1977; Burri, 1984) . The mesenchyme surrounding the endoderm gives rise to blood vessels and interstitial cells. In the mature lungs, large pulmonary vessels branch with the airways and capillaries form an intimate association with alveolar epithelium. This precise alignment between lung epithelial cells and the vasculature is critical for lung function as a gas-exchange organ. The close anatomical relationship between airways and blood vessels in the lungs suggests that the development of the two systems has to be tightly coordinated, and that there may be reciprocal inductive interactions between epithelial and endothelial cells. The regulation of epithelial branching morphogenesis has been extensively studied and many genes have been identified that function in lung epithelial development (Perl and Whitsett, 1999; Warburton et al., 2000; Cardoso, 2001) . In contrast, despite the importance of the vasculature as a critical functional component of the lungs, and the potential role of the vasculature in regulating the epithelial morphogenesis, the molecular mechanisms that regulate lung vessel formation are poorly understood.
Vascular endothelial growth factor (VEGF or VEGF-A) is a polypeptide growth factor for endothelial cells (Ferrara et al., 2003) . VEGF-A is critical for vascular development in a dose-dependent manner. Lacking even one allele of the VEGF-A gene leads to embryonic lethality with impaired vessel formation (Carmeliet et al., 1996; Ferrara et al., 1996) . Endothelial cell development is delayed, and vessel sprouting, remodeling, and survival are impaired. Two high affinity VEGF-A receptors, belonging to the receptor tyrosine kinase family, have been identified, VEGFR-1, or Flt-1 (fems-liketyrosine kinase), and VEGFR-2, or Flk-1 (fetal liver kinase). Deficiency in either VEGF receptor also leads to abnormal embryonic vascular development. A null mutation in VEGFR-2 results in lack of a vasculature and very few endothelial cells, suggesting that Flk-1 functions in the differentiation and/or proliferation of endothelial cells (Shalaby et al., 1995) . In contrast, mice deficient in VEGFR-1 (Flt-1) have excess endothelial cells that are not organized into normal tubular networks (Fong et al., 1995) .
A role for VEGF and VEGF receptors in lung vascular development is suggested by their pattern of expression. In embryonic lungs, VEGF-A is expressed mainly by epithelial cells, while the VEGF receptors are expressed by mesenchymal cells (Millauer et al., 1993; Peters et al., 1993; Schachtner et al., 2000; Ng et al., 2001; Greenberg et al., 2002) . The complementary pattern of expression of ligand and receptors suggests inductive interactions between epithelium and mesenchyme in the formation of lung blood vessels. The role of VEGF-A in the development of the lung vasculature is unknown, as mice heterozygous for a null allele of the VEGF-A gene die in early embryogenesis, before lung development begins. However, several studies suggest that VEGF-A does indeed function in lung vascular and epithelial development. Capillary formation in lung organ cultures is stimulated by VEGF-A, and lung development in mice over-expressed one or all VEGF-A isoforms in lung epithelium or engineered to express only one VEGF isoform is abnormal (Akeson et al., 2003; Galambos et al., 2002; Healy et al., 2000; Ng et al., 2001) .
We have recently developed a lung renal capsule allograft model that follows closely lung development in utero (Vu et al., 2003) . In this model, mouse embryonic lung explants are implanted underneath the kidney capsules of syngeneic or immunodeficient host mice and allowed to develop for up to 8 days. We observe extensive development of both epithelium and blood vessels. The epithelium progresses through all the embryonic stages of lung development including sacculation. Blood vessels develop from intrinsic endothelial cell precursors and form both large caliber vessels that accompany airways as well as capillaries in the saccular walls. In the present study, we characterize the expression of VEGF-A and its receptors during embryonic lung development, and inhibit its activity using soluble VEGFR-1 (mFlt-Ig) in the lung renal capsule allograft model to study the role of VEGF-A in lung vascular and epithelial development.
Results

VEGF-A and its receptors are expressed during mouse embryonic lung development
To gain an understanding of the function of VEGF-A in lung development, we first characterized in detail the cellular expression of VEGF-A and its two receptors, Flt-1 (VEGFR-1) and Flk-1 (VEGFR-2), during embryonic lung development by in situ hybridization with 35 S-labeled antisense riboprobes on tissue sections of embryonic lungs at E12.5, E13.5, E14.5, E16.5, and E18.5. We found low level of VEGF-A expression at E14.5 and higher expression of VEGF-A at E16.5 and E18.5 (Fig. 1) . Even though embryonic lungs at E12.5 and E13.5 did not show significant expression of VEGF-A by in situ hybridization, VEGF-A expression at these stages was detectable by RT-PCR (data not shown). By in situ hybridization, at E14.5, VEGF-A was expressed at a low level in epithelial cells and in the mesenchyme (Fig. 1B) . At E16.5, VEGF-A expression increased to high levels in the distal epithelium (Fig. 1C) . By E18.5, high VEGF-A expression was restricted to a subpopulation of cells that line the saccular walls (Fig. 1D ). The location of these cells is consistent with type II epithelial cells, however, since epithelial cells are closely apposed to other cells in the saccular walls, we cannot rule out expression by other cells.
Interestingly, the expression of VEGF receptors was detected earlier than that of VEGF. Both receptors had similar expression patterns throughout the lungs, starting at least as early as E12.5, and continuing throughout development. At E12.5-E16.5 expression of the VEGF receptors were found in mesenchymal cells surrounding the epithelium (Fig. 1E -G,I-K) as well as in endothelial cells lining large vessels (data not shown). There was no epithelial expression of the receptors noted at these stages. At E18.5 VEGF receptor expression was found in endothelial cells lining large vessels (data not shown) as well as in a subpopulation of cells in the saccular walls (Fig. 1H,L) . Because of the close proximity of epithelial and endothelial cells in the saccular walls, it is unclear whether these receptor expressing cells are epithelial or endothelial in this location.
2.2. VEGF-A is expressed during development of lung renal capsule allografts E12.5 lung explants implanted under the kidney capsule proceed through stages that resemble the pseudoglandular, canalicular, and saccular stages of embryonic lung development ( Fig. 2A-C) , as described previously (Vu et al., 2003) . Expression of VEGF-A in the lung grafts recapitulated its expression in embryonic lungs. VEGF-A was expressed by epithelial cells in 4-day lung grafts, becoming restricted to the distal epithelial cells in 6-day lung grafts, and in the 8 day-lung grafts, its expression was restricted to a population of epithelial cells in the saccular walls (Fig. 4D-F) . These distributions resemble VEGF-A expression patterns in the pseudoglandular, canalicular, and saccular stages of embryonic development, respectively.
Inhibition of VEGF-A activity results in abnormal epithelial and vascular development in lung renal capsule allografts
To determine the role of VEGF-A in the development of blood vessels, we inhibited its activity in lung renal capsule allografts using a soluble receptor, mFlt(1-3)-Ig. This chimeric protein contains the first three immunoglobulin domains of the extracellular ligand-binding domain of mouse Flt-1 (VEGFR-1) fused to the Fc portion of a mouse IgG molecule. It effectively inhibits VEGF-A activity by binding to and sequestering it (Ferrara et al., 1998; Gerber et al., 1999) .
Systemic administration of mFlt(1-3)-Ig to host mice harboring embryonic lung renal capsule grafts altered the development of both epithelium and vasculature in the grafts. After 3 days, both mFlt(1-3)-Ig-treated and untreated lung grafts had branching epithelial tubes, consistent with the pseudoglandular stage of development (Fig. 3A,B ). There were no significant differences in the size of the grafts and in epithelial morphology in treated and untreated grafts. However, blood vessel development in the grafts was inhibited by mFlt(1-3)-Ig treatment, as assayed by immunostaining for an endothelial cell marker, CD31 (PECAM-1). Capillaries surrounding the epithelial tubes were present in the untreated, but not in the treated grafts (Fig. 3C,D) . The treated grafts also showed areas of hemorrhage (Fig. 3B) .
After 6 days of treatment, the untreated lung grafts had reached the canalicular stage of development with branching distal airspaces lined by attenuated epithelium (Fig. 3E) . However, in the mFlt(1-3)-Ig treated lung grafts, S labeled antisense probes against VEGF-A (A-D), VEGFR-1 (E-H), and VEGFR-2 (I-L). At E12.5, VEGF-A is not expressed either in epithelium (A, arrowhead) or mesenchyme (A, arrow); At E14.5, it is expressed in both epithelium (B, arrowhead) and mesenchyme (B, arrow); at E16.5 it is expressed in distal epithelial cells (C, arrowheads); at E18.5, it is expressed in a subpopulation of cells in the saccular wall (D, arrows). VEGFR-1 and VEGFR-2 are expressed in mesenchymal cells at E12.5-E16.5 (E-G, I-K arrows) but not in epithelial cells (E-G, I-K, arrowheads). At E18.5, VEGFR-1 and VEGFR-2 are expressed in cells in the saccular walls (H,L, arrows). Bar: 50 mm.
there were only few branching distal airspaces. Instead, we observed areas of compacted epithelial tubes lined by cuboidal epithelial cells, and areas of more attenuated epithelial cells that were not organized into any particular structures (Fig. 3F ). CD31 immunostaining showed different sized vessels as well as extensive capillary networks surrounding the airspaces in the untreated grafts (Fig. 3G ). However, in the grafts treated with mFlt(1-3) Ig, there were no capillary networks and only a few dilated vascular spaces formed (Fig. 3H) .
By day 8 the untreated lung grafts were at the saccular stage of lung development with the presence of bronchi (large airways lined by ciliated epithelium) and bronchioles (smaller airways lined by cuboidal epithelium), as well as saccular structures (Fig. 4A,C) . In contrast, the lung grafts treated with mFlt(1-3)-Ig for 8 days were smaller and showed significantly different epithelial morphology (Fig. 4B ). There were few large airways and no saccular development. Instead, we observed areas where layers of attenuated epithelium were not organized into saccules, but appeared to be loosely arranged sheets of cells (Fig. 4D ). These cells resembled epithelial cells that normally make up the saccular walls. However, they were not organized into saccules. In other areas, epithelial tubes lined by cuboidal epithelial cells were compacted together (Fig. 4E) and apoptotic ( Fig. 4F-I ). Immunostaining for CD31 showed there were only a few dilated vascular spaces and no capillaries in the treated grafts (Fig. 5B) . In contrast, there were both large caliber vessels and extensive network of capillaries in the saccular walls in the untreated lung grafts (Fig. 5A) . At high magnification capillaries were seen in between the layers of attenuated epithelial cells that lined the saccules in the untreated grafts (Fig. 5C) . However, the treated grafts had no capillaries in between the disorganized layers of attenuated epithelial cells (Fig. 5D ).
Inhibition of VEGF-A activity results in reduced epithelial proliferation, but permits differentiation in lung renal capsule allografts
These results led us to ask whether the lack of vascular formation in the lung grafts leads to alteration in epithelial cell proliferation and/or differentiation. We assayed for proliferating cells by BrdU incorporation and for epithelial cell differentiation by cell type-specific markers. After 3 and 6 days of grafting, there was extensive cell proliferation evidenced by BrdU incorporation in both epithelial and mesenchymal cells in the untreated lung grafts (Fig. 6A,C) . Treatment with mFlt(1-3)-Ig resulted in no significant change in cell proliferation at 3 days (Fig. 6B) , but severely reduced cell proliferation at 6 days. In the 3-day lung grafts, the percentage of proliferating cells in the mesenchyme was 42%G2.3 in the control vs. 45%G2.6 in the treated grafts. In the epithelium, the percentage of proliferating cells was 44%G5.6 in the control grafts and showed a wide range (30%G13) in the treated grafts. In the 6-day treated grafts, there were only a few scattered areas of proliferating cells in contrast to widespread number of proliferating cells in the control grafts (Fig. 6C,D) .
To determine if epithelial cell differentiation is affected by inhibition of VEGF-A activity, we assayed for the expression of Clara cell specific protein (CCSP), surfactant associated protein C (SP-C), and aquaporin 5 (AQP5). CCSP is normally expressed in nonciliated bronchiolar epithelial (Clara) cells and indicates proximal differentiation (Hackett et al., 1992; Strum et al., 1992) . Type II epithelial cells in the saccular walls express SP-C, indicating distal differentiation (Kalina et al., 1992) . AQP5 is expressed by type I epithelial cells in the saccular walls (Funaki et al., 1998) . We found that CCSP, SP-C, and AQP5 expression continued with mFlt(1-3)IgG treatment. In the 8-day untreated lung grafts, CCSP was expressed in nonciliated bronchiolar epithelial cells (Fig. 6E) , SP-C was expressed in a subpopulation of the epithelial cells in the saccular walls with rounded morphology consistent with type II epithelial cells (Fig. 6G) , and AQP5 was expressed in epithelial cells lining the saccular walls with flattened morphology consistent with type I epithelial cells (Fig. 6I) . Interestingly, even though treatment with mFlt(1-3)-Ig altered graft morphology, the expression of CCSP, SP-C, and AQP5 continued. In the 8-day treated lung grafts, CCSP expression was found in nonciliated epithelial cells (Fig. 6F) , and SP-C and AQP5 expression was found in cells in the layers of attenuated epithelial cells, even though these were not organized into saccules (Fig. 6H,J) .
Discussion
VEGF-A is necessary for lung vascular development
In this study we have extended previous studies showing that VEGF-A and its two receptors, VEGFR-1 (Flt-1) and VEGFR-2 (Flk-1), have complementary expression during embryonic lung development. We have also used a model of lung development, lung renal capsule allografts, to show that VEGF-A activity is necessary for the proper development of both endothelial and epithelial cells.
The pattern of expression of VEGF-A and of its receptors is consistent with the hypothesis that paracrine interactions participate in the coordination between airway and blood vessel development. VEGF-A expressed by epithelium may stimulate vessel formation in the surrounding mesenchyme. Lung vessels form as capillary networks in the mesenchyme surrounding the branching epithelial tubes during the pseudoglandular stage. These subsequently remodel into larger caliber vessels that accompany the airways. During the canalicular and saccular stages, capillaries form around the branching distal airspaces and form a capillary network in between and apposed to the layers of epithelium that line adjacent airspaces. The expression of VEGF-A in branching 
There are also areas of hemorrhage (asterisks). (G,H) PECAM immunostaining of tissue sections of 6-day untreated (G) and treated (H) grafts.
There is an extensive network of capillaries in the untreated grafts (G, arrows) as well as larger caliber vessels (arrowheads), but no capillaries in the treated grafts (H). Bar: A,B, E-H, 100 mm; C,D, 50 mm. distal epithelium during the canalicular stage is specifically suggestive of its role in stimulating blood vessel formation during the development of the distal lung. Inhibition of VEGF-A activity by sequestration with soluble receptor resulted in inhibition of endothelial cell development in lung renal capsule grafts. There were no capillaries forming around the proximal airways during the pseudoglandular stage or around the distal airspaces during the canalicular and saccular stages. The few dilated vascular spaces that are found in the treated grafts may be from vessels that are already present in the lung rudiments at the time of grafting. Since blood vessel development in lung allografts likely recapitulates its development in utero, it is likely that VEGF-A is also required for embryonic lung vessel development in vivo. Even though mFlt(1-3)-Ig also binds PlGF and VEGF-B (Olofsson et al., 1998; Park et al., 1994) , the effect observed is most likely due to inhibition of VEGF-A. PlGF-null and VEGF-B null mice have no phenotypic abnormalities (Bellomo et al., 2000; Carmeliet et al., 2001 ). Thus it is unlikely that their inhibition by mFlt(1-3)-Ig has an effect on lung graft vessel development. However, we cannot rule out additive or synergistic effects among these three Flt-1 ligands.
In support of this conclusion, previous studies have shown that exogenously applied VEGF-A can stimulate angiogenesis in lung mesenchyme in lung organ cultures and that increased expression of VEGF-A in lung epithelium in transgenic mice resulted in increased lung vascularity and abnormal epithelial development (Zeng et al., 1998; Healy et al., 2000) . In addition, the lungs of mice engineered to express only the VEGF120 isoform are hypomorphic, with decreased formation of distal capillaries and enlarged airspaces (Ng et al., 2001; Galambos et al., 2002) . This suggests that the larger isoforms are necessary for the full development of the distal lungs. Interestingly, over-expression of the VEGF164 isoform led to altered lung epithelial morphogenesis in a pattern dependent on whether the exogenous VEGF164 was expressed in proximal or distal lung epithelium (Akeson et al., 2003) . Thus both the level of VEGF-A as well as the sites and differential expression of its isoforms are critical for normal lung vascular and epithelial development.
The vasculature is important for distal lung morphogenesis, but does not regulate epithelial differentiation
Inhibition of VEGF-A led to significant alteration in epithelial development. This may be due to lack of VEGF-A function in epithelial cells or an indirect effect through inhibition of vascular development. Our expression study showed that there was no significant expression of VEGFR-1 and -2 on epithelial cells, even though we cannot ruled out the expression of VEGF receptors on epithelial cells at E18.5 as it is difficult to distinguish between epithelial and endothelial cells in the saccular walls. However, studies using flk.LacZ mice or in situ hybridizations by other investigators did not demonstrate expression of VEGF receptors by lung epithelial cells (Akeson et al., 2003; Gebb and Shannon, 2000; Schachtner et al., 2000) . In addition, since we observed alteration in epithelial development prior to saccular development, this effect is more likely secondary to inhibition of endothelial cell development and not to a direct effect on epithelial cells. At 6 days, untreated grafts showed development of distal acini into elongated branched tubular structures lined by attenuated epithelium typical of the canalicular stage. The treated grafts had few of these structures. Instead, there were areas of compacted epithelial tubes lined by cuboidal epithelial cells and areas of disorganized attenuated epithelial cells. Thus, either distal lung growth and branching are inhibited or the distal epithelium may have continued to grow and differentiate into attenuated cells, but the morphogenesis of these cells into branching air spaces is impaired. The alteration of distal airspace development was accompanied by reduced cell proliferation as evidenced by decreased BrdU incorporation. At 8 days, untreated lung grafts showed saccular development with the branched distal air spaces having been further subdivided into saccules. In the treated grafts, no saccules were formed. Instead there continued to be areas of compacted epithelial tubes lined by cuboidal epithelial cells containing large number of apoptotic cells and areas of disorganized attenuated epithelial cells. Interestingly, these cells showed expression of the distal epithelial cell markers SP-C and AQP5. Thus it appears that without the vasculature the distal epithelium either stops developing, becomes compacted and undergoes apoptosis, or continues to grow and differentiate into attenuated epithelium and express distal markers such as SP-C and AQP5, but cannot organize into saccules.
Two overlapping roles for the vasculature in the proper morphogenesis of the epithelium can be envisioned. One is that the vasculature is necessary to provide oxygen and nutrients to the growing epithelium and mesenchyme, and without the vasculature, epithelial and mesenchymal cells cease growth and development and undergo apoptosis. Alternatively, besides vascular function, the vasculature, and in particular endothelial cells, may also provide growth and/or morphogenetic signals to the epithelium, either directly or indirectly through other mesenchymal cells. Previous studies have implicated endothelial cells in the growth and differentiation of endodermal derivatives such as the liver and pancreas (Lammert et al., 2001; Matsumoto et al., 2001 ). The impairment of distal lung morphogenesis in VEGF-A transgenic mice and in mice expressing only the VEGF120 isoform suggests that proper epithelial development does indeed depend on normal vessel development (Zeng et al., 1998; Healy et al., 2000) . Even though it is not possible to distinguish between vascular function and an inductive function of endothelial cells in distal lung morphogenesis in the current study, we propose that both functions are contributory. Even though there were no endothelial cells, and thus no blood vessels, in the lung grafts after 6 and 8 days of treatment, there were still areas of epithelial cells that survived and expressed differentiation markers. This suggests that cells in these areas do not need blood vessels to survive and differentiate. In our model, blood vessels are present near the explants and may provide for a sufficiently oxygenated environment. Our data on the expression of VEGF-A in lung renal capsule grafts suggest that the lung grafts are not hypoxic. VEGF-A expression in the lung grafts is not changed from its normal developmental expression in the lungs (Fig. 2) . If the lung grafts were hypoxic, induction of VEGF-A expression would be expected. However, lack of endothelial cell 
Experimental procedures
4.1. Transplantation of embryonic lung rudiments underneath the renal capsule and treatment with mFlt(1-3)-Ig E12.5 lungs were dissected from pregnant C57BL6 or C3H mothers (the day of the vaginal plug is considered E0.5) and placed in PBS on ice. Adult host mice were anesthetized, and the kidney exposed through a dorsal incision. An incision was made in the thin membranous capsule, and individual E12.5 lung was placed as a whole underneath the capsule. Two lungs were placed per kidney, and either one or both kidneys were used. After grafting, the kidney was placed back into its position, the muscle layer was closed with silk sutures, and the skin was stapled. C57BL6 lungs were grafted into C57BL6 and C3H lungs were grafted into C3H hosts, respectively. Host mice were injected intraperitoneally daily with either PBS or mFlt(1-3)Ig (Genentech) made in PBS at doses of 25 mg/(g/d). After 3, 6, or 8 days (the day of grafting is day 0), the host mice were sacrificed and the grafts removed for analysis. 
Histological analysis and immunohistochemistry
After removal, lung grafts were fixed in 4% paraformaldehyde at 4 8C overnight and processed for paraffin sections. For histological analysis, sections were stained with hematoxylin and eosin. For immunohistochemistry with CD31 (PECAM-1) and AQP5 antibodies, sections were deparaffinized, washed in PBS, quenched in PBS C3% H 2 O 2 for 5 min, washed in PBS, then briefly treated with either 0.1% trypsin made in PBS for a few minutes at 37 8C (for CD31 immunohistochemistry) or with antigen unmasking solution (Vector Laboratory, Burlingame, CA) per manufacturer's instruction (for AQP5 immunohistochemistry). The slides are then washed in PBS and blocked in PBS C2% normal serum for 2 h. The sections were then incubated with rat monoclonal anti-mouse CD31 antibody (clone MEC 13.3, Pharmingen, San Diego, CA) diluted 1:100 in PBS C 1 mg/ml BSA at 4 8C overnight. Following primary antibody incubation, the slides were washed in PBS, incubated with biotinylated secondary antibody for 1 h, washed in PBS, then incubated with Vector Elite ABC reagent (Vector Laboratory, Burlingame, CA) for 1 h, washed in PBS, and developed with DAB substrate. For immunohistochemistry with proSP-C and CCSP antibodies, the sections were deparaffinized, washed in PBS, quenched in methanol C0.5% H 2 O 2 for 5 min, washed in PBS, pH 7.2, then blocked in 0.1 M phosphate buffer pH 7.4C0.2% Triton X-100 and 2% normal serum for 2 h. The sections were then incubated with primary antibody diluted in 0.1 M phosphate buffer pH 7.4C0.2% Triton X-100C1 mg/ml BSA at 4 8C overnight. Following primary antibody incubation, the slides were washed in 0.1 M phosphate buffer pH 7.4C0.2% Triton X-100, incubated with biotinylated secondary antibody for 1 h, washed in 0.1 M phosphate buffer pH 7.4C0.2% Triton X-100, then incubated with Vector Elite ABC reagent (Vector Laboratory, Burlingame, CA) for 1 h. The slides were then washed in 0.1 M phosphate buffer pH 7.5C0.2% Triton X-100, and developed with DAB substrate. Rabbit anti human proSP-C antibody is from Chemicon (Temecula, CA) and was used at dilution 1:500. Rabbit anti-rat CCSP antibody is a gift from Dr Gurmukh Singh (Department of Veteran Affairs, Pittsburg Health Care Systems, Pittsburgh, PA) and was used at dilution 1:2000. Goat anti-aquaporin 5 antibody is from Santa Cuz Biotechnology, Inc. (Santa Cruz, CA) and was used at dilution 1:100.
Detection of BrdU-labeled and apoptotic cells
Mice were injected intraperitoneally with 10 mg/ml BrdU (Sigma, St Louis, MO) at doses of 0.01 ml/g 1 h prior to sacrifice. Lung grafts were removed and processed for paraffin sections as above. Slides were immunostained with an antibody against BrdU using a kit from Zymed (South San Francisco, CA). Apoptotic cells were identified with the TUNEL method with fluorescein-conjugated antibody using a kit from Intergen (Purchase, NY). For quantification of BrdU labeled cells, photographs were taken of areas of epithelium or mesenchyme, and the number of BrdU positive and negative cells in each area was manually counted. The percentage of proliferating cells was computed as the percentage of BrdU positive cells over total cell number (BrdU positive and negative).
In situ hybridization
For in situ hybridization with 35 S-labeled probes, slides were deparaffinized, treated with proteinase K (20 mg/ml) for 5 min at ambient temperature, and hybridized with antisense or sense riboprobes in hybridization buffer (50% deionized formamide, 300 mM NaCl, 20 mM Tris-HCl pH 8.0, 5 mM EDTA, 0.5 mg/ml yeast tRNA, 10% dextran sulfate, and 1! Denhardt's) in a humidified chamber at 55 8C overnight. Following hybridization, the slides were treated with Rnase A, washed to a final stringency of 50% formamide, 2! SSC at 60 8C, dipped in emulsion, exposed for 1-2 weeks, developed, and counterstained with hematoxylin and eosin.
For in situ hybridization with digoxigenin-labeled probes, slides were deparaffinized, treated with proteinase K (5 mg/ml) for 10 min at ambient temperature, and hybridized with anti-sense or sense riboprobes in hybridization buffer (50% deionized formamide, 600 mM NaCl, 10 mM Tris-HCl pH 7.5, 1 mM EDTA, 0.25% SDS, 0.2 mg/ml yeast tRNA, 10% dextran sulfate, and 1! Denhardt's) in a humidified chamber at 50 8C overnight. Following hybridization, the slides were washed to a final stringency of 0.2! SSC at 50 8C and subjected to immunostaining with anti-Dig antibody conjugated to alkaline phosphatase (Roche Biosciences, Indianapolis, IN), developed with NBT/BCIP substrate, and counterstained with nuclear fast green.
